A retrospective assessment of the effectiveness of fenofibrate 267 mg on high-density lipoprotein cholesterol levels in patients attending a lipid clinic

Clinical Therapeutics

Volumn 24, Issue 7, 2002, Pages 1154-1160

  Le Roux, Carel W ^a   Murphy, Elaine ^a   Seed, Mary ^a  

^a CHARING CROSS HOSPITAL   (United Kingdom)

Author keywords

Fenofibrate; High density lipoprotein cholesterol; PPAR

Indexed keywords

FENOFIBRATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; TRIACYLGLYCEROL; ANTILIPEMIC AGENT; CELL RECEPTOR; TRANSCRIPTION FACTOR;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CHOLESTEROL BLOOD LEVEL; CLINICAL PRACTICE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; RETROSPECTIVE STUDY; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; UNITED KINGDOM; BLOOD; COMPARATIVE STUDY; DRUG POTENTIATION; HYPERLIPIDEMIA; METABOLISM; MIDDLE AGED; OUTPATIENT DEPARTMENT; STATISTICS; UNIVERSITY HOSPITAL;

ANTILIPEMIC AGENTS; CHOLESTEROL, HDL; FEMALE; HOSPITALS, UNIVERSITY; HUMANS; HYPERLIPIDEMIAS; MALE; MIDDLE AGED; OUTPATIENT CLINICS, HOSPITAL; PROCETOFEN; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RETROSPECTIVE STUDIES; TRANSCRIPTION FACTORS; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 0036022899     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(02)80026-1     Document Type: Article

References (17)

1. The Tromso heart-study. High-density lipoprotein and coronary heart-disease: A prospective case control study
2. High density lipoprotein as a protective factor against coronary heart disease. The Framingham study
3. High density lipoprotein cholesterol and myocardial infarction or sudden death: A prospective case-control study in middle-aged men of the Oslo study
4. High-density lipoprotein - The clinical implication of recent studies
5. High density lipoprotein cholesterol as a predictor of cardiovascular disease mortality in men and women: The follow-up study of the Lipid Research Clinics Prevalence study
6. HDL cholesterol and cardiovascular disease. Four prospective American studies
7. Joint British recommendations on prevention of coronary heart disease in clinical practice: Summary
8. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
9. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: The Diabetes Atherosclerosis Intervention Study, a randomised study
10. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol
11. Effects of fenofibrate on high and low density lipoprotein metabolism in heterozygous familial hypercholesterolemia
12. Effect of fenofibrate on lipids, lipoproteins, and apolipoproteins in 33 subjects with primary hypercholesterolemia
13. Efficacy and tolerance of 200 mg micronised fenofibrate administered over a 6-month period in hyperlipidaemic patients: An open Belgium multicenter study
14. Effectiveness and tolerability of 12-week treatment with micronised fenofibrate 200 mg in a drug monitoring programme involving 9884 patients with dyslipidaemia
15. Micronized fenofibrate or gemfibrozil in patients with combined hyperlipidaemia: A double blind multicentre trial
16. The impact of micronized fenofibrate on lipid subfractions and on reaching HDL targets in 7098 patients with dyslipidaemia
17. Drug therapy of hyperlipidaemias